BMS' Zeposia (ozanimod) Receives the US FDA's Approval for Ulcerative Colitis
Shots:
- The approval is based on a P-III True North trial assess Zeposia (0.92 mg) vs PBO in an adult with mod. to sev. active UC
- The trial met its 1EPs & 2EPs i.e Zeposia as an induction & maintenance therapy demonstrates clinical remission (18% vs 6% & 37% vs 19%)- clinical response (48% vs 26% & 60% vs 41%)- endoscopic improvement (27% vs 12% & 46% vs 26%)- endoscopic-histologic mucosal improvement (13% vs 4% & 30% vs 14%) @10 & 52 wks. respectively. Reduction in rectal bleeding & stool frequency subscores observed @2wks.
- The MAA for the therapy is currently under EMA review with the expected regulatory decision in H2’21. The Zeposia 360 Support program will care for patients with UC
Ref: BMS | Image: BMS
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com